Aug 7, 2026 08:45AM
May 20, 2026 04:45PM
May 8, 2026 08:45AM
May 6, 2026 08:31AM
May 6, 2026 08:30AM
May 4, 2026 08:30AM
May 4, 2026 08:30AM Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome
Mar 27, 2026 06:46AM
Mar 25, 2026 05:30PM
Mar 19, 2026 11:00AM
Mar 19, 2026 08:00AM
Feb 11, 2026 08:31AM
Feb 11, 2026 08:30AM
Feb 5, 2026 08:31AM Atossa maintains eligibility for priority review voucher after program renewal
Feb 5, 2026 08:30AM
Jan 16, 2026 04:40PM
Jan 6, 2026 08:15AM
Jan 6, 2026 08:15AM
Dec 11, 2025 08:02AM
Dec 11, 2025 08:00AM
Dec 5, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Atossa Genetics (ATOS)
Dec 4, 2025 08:01AM
Dec 4, 2025 08:00AM
Nov 17, 2025 09:09AM
Nov 17, 2025 09:07AM
Nov 12, 2025 08:15AM
Oct 7, 2025 06:47AM
Oct 1, 2025 08:32AM Atossa Therapeutics appoints Janet Rea as senior VP of R&D
Oct 1, 2025 08:30AM
Sep 9, 2025 06:52AM
Sep 8, 2025 08:30AM
Sep 8, 2025 08:30AM
Aug 28, 2025 08:30AM
Aug 20, 2025 08:30AM
Aug 12, 2025 08:30AM Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update
Jul 29, 2025 07:45AM
Jul 29, 2025 07:45AM
May 20, 2025 09:00AM
May 14, 2025 08:15AM
May 13, 2025 08:00AM
Apr 30, 2025 08:45AM
Apr 30, 2025 08:45AM Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
Apr 29, 2025 08:47AM
Apr 29, 2025 08:45AM
Apr 22, 2025 08:45AM
Apr 22, 2025 08:45AM
Mar 26, 2025 06:52AM
Mar 25, 2025 08:00AM
Mar 11, 2025 08:15AM Atossa Therapeutics (ATOS) Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
Mar 11, 2025 08:15AM

329,909 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All